Success Metrics

Clinical Success Rate

78.6%

Based on 11 completed trials

Completion Rate

79%(11/14)

Active Trials

3(16%)

Results Posted

9%(1 trials)

Terminated

3(16%)

Phase Distribution

Ph not_applicable

Ph phase_2

32%

Ph phase_3

42%

Ph phase_4

21%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution19 total trials

Phase 2Efficacy & side effects

6(31.6%)

Phase 3Large-scale testing

8(42.1%)

Phase 4Post-market surveillance

4(21.1%)

N/ANon-phased studies

1(5.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.6%

11 of 14 finished

Non-Completion Rate

21.4%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(11)

Terminated(3)

Other(2)

Detailed Status

Completed11

Terminated3

Recruiting3

unknown2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

78.6%

Most Advanced

Phase 4

Trials by Phase

Phase 26 (31.6%)

Phase 38 (42.1%)

Phase 44 (21.1%)

N/A1 (5.3%)

Trials by Status

terminated316%

unknown211%

completed1158%

recruiting316%

Recent Activity

3 active trials

Showing 5 of 19

recruitingphase_2

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

NCT04310930

recruitingphase_3

Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit

NCT05696093

recruitingphase_2

Clinical Trials (19)

Showing 19 of 19 trials

NCT04310930Phase 2

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting

NCT05696093Phase 3

Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit

Recruiting

NCT05835479Phase 2

Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

Recruiting

NCT04884490Phase 2

The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients

Completed

NCT02773407Phase 3

Nepal Undifferentiated Febrile Illness Trial

Completed

NCT03187834Phase 4

Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso

Completed

NCT04985110Phase 2

Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital

Unknown

NCT03087890Phase 4

Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria

Completed

NCT00330304Phase 3

Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children

Completed

NCT01777737Phase 3

Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole

Terminated

NCT01701297Phase 2

VSL#3 and Spontaneous Bacterial Peritonitis

Terminated

NCT00711906Phase 3

Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy

Terminated

NCT00427076Phase 3

Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections

Completed

NCT01832987Phase 2

Pharmacokinetic Parameters of Co-trimoxazole

Completed

NCT00970879Phase 3

Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine

Completed

NCT01086878Phase 4

Safety of Cotrimoxazole in HIV- and HAART-exposed Infants

Completed

NCT00933049Phase 3

Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months

Completed

NCT00355602Not Applicable

Antibiotics for the Treatment of Ulcerative Colitis

Completed

NCT00674921Phase 4

Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda

Unknown

All 19 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 19